Biocon Biologics Ltd received UK approval for Vevzuo and Evfraxy, biosimilars of Denosumab. Vevzuo is approved for ...

Biocon Biologics receives marketing authorizations for Vevzuo and Evfraxy biosimilars for bone-related diseases in the UK.

Vevzuo is authorized for the prevention of skeletal related events (pathological fracture, radiation to bone, spinal cord ...

New Delhi: Biocon Ltd on Monday said its arm Biocon Biologics Ltd has received marketing authorisations from the Medicines ...

Biocon Ltd. plans to file for regulatory approvals of generic versions of Novo Nordisk A/S’s Ozempic and Wegovy in key ...

Biocon Biologics announced that the Medicines and Healthcare products Regulatory Agency (MHRA) granted marketing authorisations in the United Kingdom (UK) for Vevzuo and Evfraxy, biosimilars of ...

Biocon share price gained 2.5 per cent after reports suggested that the company is planning to file for generic versions of ...

Biocon Biologics receives UK MHRA approval for Vevzuo & Evfraxy, biosimilars of Denosumab, to treat bone diseases in adults & ...

Clinical studies have demonstrated that both biosimilars are comparable in safety and efficacy to the reference product, the ...

Bengaluru: Biocon Biologics Ltd, a fully integrated global biosimilars company and subsidiary of Biocon Ltd., has received ...